Following the strong 1H26 results publication, IXICO has announced two new business wins for its imaging Contract Research Organisation (iCRO). A new contract will see IXICO provide analytics to validate a blood-based biomarker (BBB) test for Alzheimer’s disease (AD) and the company has received a contract extension for an existing Phase 2 Huntington’s disease (HD) clinical trial. The combined value of these contract wins is £1.3m to be delivered over a two-year period. With the 1H26 results, IX ....
